UROXATRAL Drug Patent Profile

✉ Email this page to a colleague

When do Uroxatral patents expire, and when can generic versions of Uroxatral launch?

Uroxatral is a drug marketed by Concordia and is included in one NDA.

The generic ingredient in UROXATRAL is alfuzosin hydrochloride. There are nineteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the alfuzosin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Uroxatral

A generic version of UROXATRAL was approved as alfuzosin hydrochloride by APOTEX INC on July 18^th, 2011.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for UROXATRAL?
What are the global sales for UROXATRAL?
What is Average Wholesale Price for UROXATRAL?

Summary for UROXATRAL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	4
Patent Applications:	267
Drug Prices:	Drug price information for UROXATRAL
Drug Sales Revenues:	Drug sales revenues for UROXATRAL
What excipients (inactive ingredients) are in UROXATRAL?	UROXATRAL excipients list
DailyMed Link:	UROXATRAL at DailyMed

Drug patent expirations by year for UROXATRAL

Recent Clinical Trials for UROXATRAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sanofi	N/A
University Hospitals Cleveland Medical Center	N/A
University of Pennsylvania	Phase 3

See all UROXATRAL clinical trials

Pharmacology for UROXATRAL

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Paragraph IV (Patent) Challenges for UROXATRAL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
UROXATRAL	Extended-release Tablets	alfuzosin hydrochloride	10 mg	021287	9	2007-06-12

US Patents and Regulatory Information for UROXATRAL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Concordia	UROXATRAL	alfuzosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021287-001	Jun 12, 2003	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for UROXATRAL

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Concordia	UROXATRAL	alfuzosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021287-001	Jun 12, 2003	⤷ Sign Up	⤷ Sign Up
Concordia	UROXATRAL	alfuzosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021287-001	Jun 12, 2003	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for UROXATRAL

See the table below for patents covering UROXATRAL around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Turkey	9900289		⤷ Sign Up
France	2582513	COMPOSITIONS PHARMACEUTIQUES CONTENANT DE L'ALFUZOSINE	⤷ Sign Up
European Patent Office	0938318	COMPRIME A LIBERATION CONTROLEE DE CHLORHYDRATE D'ALFUZOSINE (TABLET WITH CONTROLLED RELEASE OF ALFUZOSINE CHLORYDRATE)	⤷ Sign Up
Cyprus	2284	Tablet with controlled release of alfuzosine chlorydrate	⤷ Sign Up
New Zealand	334018	MULTILAYERED CONTROLLED RELEASE TABLET COMPRISING A LAYER OF ALFUZOSIN HYDROCHLORIDE AND AT LEAST ONE LAYER OF HYDROPHILLIC POLYMERS	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration